BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28582607)

  • 1. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.
    Murata M; Maeda Y; Masuko M; Onishi Y; Endo T; Terakura S; Ishikawa Y; Iriyama C; Ushijima Y; Goto T; Fujii N; Tanimoto M; Kobayashi H; Shibasaki Y; Fukuhara N; Inamoto Y; Suzuki R; Kodera Y; Matsushita T; Kiyoi H; Naoe T; Nishida T
    Cancer Sci; 2017 Aug; 108(8):1634-1639. PubMed ID: 28582607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.
    Nishida T; Kobayashi T; Sawa M; Masuda S; Shibasaki Y; Goto T; Fukuhara N; Fujii N; Ikegame K; Sugita J; Ikeda T; Kuwatsuka Y; Suzuki R; Najima Y; Doki N; Kato T; Inagaki Y; Utsu Y; Aotsuka N; Masuko M; Terakura S; Onishi Y; Maeda Y; Okada M; Teshima T; Murata M
    Ann Hematol; 2021 Mar; 100(3):743-752. PubMed ID: 33427909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning.
    Okada M; Tasaka T; Ikegame K; Aotsuka N; Kobayashi T; Najima Y; Matsuhashi Y; Wada H; Tokunaga H; Masuda S; Utsu Y; Yoshihara S; Kaida K; Daimon T; Ogawa H
    Eur J Haematol; 2018 Apr; 100(4):335-343. PubMed ID: 29168236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
    Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
    Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.
    Kanda J; Rizzieri DA; Gasparetto C; Long GD; Chute JP; Sullivan KM; Morris A; Smith CA; Hogge DE; Nitta J; Song K; Niedzwiecki D; Chao NJ; Horwitz ME
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):867-74. PubMed ID: 20868761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
    Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S
    Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.
    Rocha V; Labopin M; Ruggeri A; Podestà M; Gallamini A; Bonifazi F; Sanchez-Guijo FM; Rovira M; Socie G; Baltadakis I; Michallet M; Deconinck E; Bacigalupo A; Mohty M; Gluckman E; Frassoni F
    Transplantation; 2013 May; 95(10):1284-91. PubMed ID: 23507699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
    Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G
    J Clin Oncol; 2019 Feb; 37(5):367-374. PubMed ID: 30523748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
    Choe HK; Gergis U; Mayer SA; Nagar H; Phillips AA; Shore TB; Smith MJ; van Besien K
    Transplantation; 2017 Jan; 101(1):e34-e38. PubMed ID: 27764032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study.
    Frassoni F; Gualandi F; Podestà M; Raiola AM; Ibatici A; Piaggio G; Sessarego M; Sessarego N; Gobbi M; Sacchi N; Labopin M; Bacigalupo A
    Lancet Oncol; 2008 Sep; 9(9):831-9. PubMed ID: 18693069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrabone Transplantation of a Single Unwashed Umbilical Cord Blood Unit with Antithymocyte Globulin-Free and Sirolimus-Based Graft-versus-Host Disease Prophylaxis: Fast Immune Reconstitution and Long-Term Disease Control in Patients with High-Risk Diseases.
    Giglio F; Xue E; Barone A; Lorentino F; Greco R; Ruggeri A; Zambelli M; Parisi C; Milani R; Clerici D; Piemontese S; Marktel S; Lazzari L; Marcatti M; Bernardi M; Corti C; Lupo-Stanghellini MT; Ciceri F; Peccatori J
    Transplant Cell Ther; 2023 Aug; 29(8):519.e1-519.e9. PubMed ID: 37244644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
    Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H
    Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
    Misawa M; Kai S; Okada M; Nakajima T; Nomura K; Wakae T; Toda A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Fujimori Y; Ogawa H; Hara H
    Int J Hematol; 2006 Jan; 83(1):74-9. PubMed ID: 16443557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].
    Sun ZM; Liu HL; Geng LQ; Zhou CY; Wang XB; Ding KY; Tong J; Zhu WB; Liu X; Wang ZY
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1660-4. PubMed ID: 22944153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.
    Sun Z; Liu H; Luo C; Geng L; Zheng C; Tang B; Zhu X; Tong J; Wang X; Ding K; Wan X; Zhang L; Yao W; Song K; Zhang X; Wu Y; Yang H; Han Y; Liu X; Zhu W; Wu J; Wang Z
    Int J Cancer; 2018 Aug; 143(3):699-708. PubMed ID: 29473150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.